| CASE REPORTS |
|
| Year : 2021 | Volume
: 1
| Issue : 2 | Page : 98-101 |
|
|
Role of palliative chemoradiation in locally advanced head and neck cancer: A case series done in a tertiary care center in Uttar Pradesh
Gulafshan Jabi, Mohsin Khan, Pavan Deepak MandigalaVenkataRamana
Department of Radiotherapy and Clinical Oncology, JN Medical College, AMU, Aligarh, Uttar Pradesh, India
Correspondence Address:
Mohsin Khan
Department of Radiotherapy and Clinical Oncology, JN Medical College, AMU, Aligarh, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bjoc.bjoc_3_22
|
|
|
Background: Shorter palliative hypofractionated schedules when given concomitantly with chemotherapy, preferably cisplatin (radiosensitizer), enhance the response rate with acceptable toxicity, resulting in better compliance of the patients. Objectives: This case series retrospectively evaluated the role of concurrent chemotherapy, preferably cisplatin, with palliative radiation 30 Gy in 10 fractions in locally advanced head and neck cancers in terms of response rates, symptoms palliation, and acute toxicities. Materials and Methods: Twenty-six patients of histologically confirmed locally advanced head and neck cancers were selected and treated during the period January 2018 and December 2020. All patients (100%) completed the treatment with an average of two follow-ups. Results: The overall response rate of 73% was observed in patients treated, and interestingly, one patient had complete response. Moreover, 100% of the patients reported improvement in at least one symptom with severity reduction in pain. As defined by the Radiation Therapy Oncology Group (RTOG) criteria for toxicity assessment, Grade 2 mucositis in 61%, Grade 1 mucositis in 11%, Grade 1 skin reaction in 15% of the patients were observed. No grade III toxicity was reported. Conclusion: Concurrent chemotherapy acts as a radiosensitizer and provides a synergistic action when coupled with radiation resulting in more efficacious control of locoregional disease of locally advanced head and neck cancers with acceptable toxicities facilitating the compliance of patients. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
